Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation    DNDN   US24823Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/25/2014 07/28/2014 07/29/2014 07/30/2014 07/31/2014 Date
2.14(c) 2.09(c) 2.1(c) 2.1(c) 2.07(c) Last
956 526 1 377 467 1 420 663 1 199 738 1 231 943 Volume
-2.28% -2.34% +0.48% 0.00% -1.43% Change
More quotes
Company
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular... 
Surperformance© rating of Dendreon Corporation
Trading Rating : Investor Rating :
More about the company
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | DNDN | US24823Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 293 M
EBIT 2014 -74,6 M
Net income 2014 -128 M
Debt 2014 343 M
Yield 2014 -
Sales 2015 343 M
EBIT 2015 -37,6 M
Net income 2015 -89,3 M
Debt 2015 430 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 2,30x
EV / Sales 2015 2,22x
Capitalization 331 M
More Financials
Latest news on DENDREON CORPORATION
1d ago DENDREON : Names W. Thomas Amick President and Chief Executive Officer
2d ago DENDREON : Change in Directors or Principal Officers, Financial Statements and E..
2d ago DENDREON : Names W. Thomas Amick President and Chief Executive Officer
06/18 DENDREON : Termination of a Material Definitive Agreement (form 8-K)
06/09 DENDREON : Change in Directors or Principal Officers, Financial Statements and E..
06/09 DENDREON : Announces Leadership Transition
05/28 DENDREON : Treatment with PROVENGE® sipuleucel-T Induces Antigen Spread Associat..
05/21 DENDREON : Submission of Matters to a Vote of Security Holders (form 8-K)
05/21 DENDREON : Announces Presentation of PROVENGE® sipuleucel-T and DN24-02 Immuno-O..
05/20 DENDREON : Treatment with PROVENGE® (sipuleucel-T) Induces Antigen Spread Associ..
05/20 DENDREON : to Present Provenge (sipuleucel-T) and DN24-02 Immuno- Oncology Data ..
05/15 DENDREON : Announces First Quarter 2014 Results
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
Dendreon Corporation : Income Statement Evolution
More Financials
EPS Revisions
Dendreon Corporation : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF